Erytech Pharma S.A. (ERYP)
| Market Cap | 35.05M |
| Revenue (ttm) | 4.75M |
| Net Income (ttm) | -61.13M |
| Shares Out | 31.02M |
| EPS (ttm) | -1.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,931 |
| Open | 1.14 |
| Previous Close | 1.13 |
| Day's Range | 1.11 - 1.14 |
| 52-Week Range | 0.98 - 9.50 |
| Beta | 1.60 |
| Analysts | Sell |
| Price Target | 5.70 (+404.4%) |
| Earnings Date | Apr 4, 2022 |
About ERYP
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-"-l... [Read more...]
Financial Performance
In 2021, Erytech Pharma's revenue was 4.18 million, an increase of 12.43% compared to the previous year's 3.72 million. Losses were -53.80 million, -26.61% less than in 2020.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ERYP stock is "Sell." The 12-month stock price forecast is 5.7, which is an increase of 404.42% from the latest price.
News
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 2 4 , 20 22
ERYTECH to Present at the H.C. Wainwright Global Investment Conference
ERYTECH to P resent at the H.C. Wainwright Global Investment Conference
ERYTECH Provides Business and Financial Update for the First Quarter of 2022
ERYTECH Provides Business and Financial Update for the First Quarter of 20 2 2
ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its ...
ERYTECH Announces Filing of 202 1 Universal Registration Document and 202 1 Annual Report on Form 20-F , as well as its 2022 financial calendar
Why Is ERYTECH Pharma (ERYP) Stock Up Today?
Today, investors are pricing in a massive divestiture and long-term supply deal into the valuation of ERYTECH and ERYP stock. The post Why Is ERYTECH Pharma (ERYP) Stock Up Today?
Best Penny Stocks to Buy as April Ends? 3 to Watch Today
Here's what you need to know about trading penny stocks on April 25th The post Best Penny Stocks to Buy as April Ends? 3 to Watch Today appeared first on Penny Stocks to Buy, Picks, News and Informatio...
Why Erytech Pharma Are Shares Moving Higher Today
Erytech Pharma SA (NASDAQ: ERYP) has sold its US manufacturing facility to Catalent Inc (NYSE: CTLT) for $44.5 million. Catalent will acquire Erytech's commercial-scale cell therapy manufacturing facili...
ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent
Catalent acquired ERYTECH's U.S. cell therapy manufacturing facility for a total consideration of USD 44.5 million
Why Erytech Pharma Shares Are Rising Today
Erytech Pharma SA (NASDAQ: ERYP) says that the results from the NOPHO sponsored Phase 2 trial of eryaspase in acute lymphoblastic leukemia (ALL) patients are published in the British Journal of Haematol...
ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British J...
ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology
ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society
ERYTECH to Present Novel Vesiculation Approach at the 24 th M eeting of the European Red Cell Society
ERYTECH to Participate in the Upcoming April Investor Conferences
ERYTECH to Participate in the Upcoming April Investor Conferences
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 20 2 1
ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI
ERYTECH Announces P resentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI
ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
ERYTECH Announces $7.85 Million Registered Direct Offering
ERYTECH Announces $ 7.85 Million Registered Direct Offering
ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance...
ERYTECH Announces P resentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI
Why Are Erytech Pharma Shares Soaring Tuesday Premarket?
Erytech Pharma SA (NASDAQ: ERYP) shares gained more than 40% during the premarket trading session. Investors are probably reacting to the U.S. patent covering methods of treating solid tumors by adminis...
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
ERYTECH Provides Business and Financial Update for the Third Quarter of 20 2 1
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal
ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference
ERYTECH to Present at the 12 th Annual Jefferies Global London Healthcare Conference In-Person Dates: November 16 th -17 th Virtual Dates: November 18 th -19 th
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic ...
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Lin...
ERYTECH Announces M aximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer